GSK3B, glycogen synthase kinase 3 beta, 2932

N. diseases: 393; N. variants: 25
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE We recently demonstrated that heat shock protein 90 (HSP90) is involved in the regulation of runt-related transcription factor 2 via the AKT/GSK-3β/β-catenin signaling pathway in OS. 31595984 2020
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 AlteredExpression disease BEFREE The expression of Wnt3α and p-GSK-3β were also significantly upregulated indicating that the Wnt/β-catenin signaling pathway was activated during the EMT of osteosarcoma driven by BMP-2. 30737824 2019
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 AlteredExpression disease BEFREE PP2A was a direct target of miR-21, which participated in the effects of ASBEL and miR-21 on the activation of phosphatidylinositol 3-kinase/protein kinase 3/glycogen synthase kinase-3β (PI3K/AKT/GSK3β) and mitogen-activated protein kinase/extracellular regulated protein kinase (MEK/ERK) signaling pathways as well as the enhancement of osteosarcoma cell proliferation, migration, and invasion. 29323740 2018
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE Glycogen synthase kinase 3β (GSK3β) is a serine/threonine kinase and is considered as a validated target in osteosarcoma therapy. 29546355 2018
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE Moreover, AKT/GSK-3β pathway was measured to illustrate the mechanism of hsa_circ_0007534 exerts in OS progression. 30142548 2018
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE PPI induced inhibition of osteosarcoma cell viability was abolished upon addition of GSK-3β specific inhibitor, CHIR99021, while PPI induced inhibition of osteosarcoma cell viability and migration were potentiated by β-catenin silencing. 28790389 2017
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 AlteredExpression disease BEFREE Inhibition of GSK-3β activity by pharmacological inhibitors or of its expression by RNA interference suppressed proliferation of osteosarcoma cells and induced apoptosis. 27780915 2016
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 AlteredExpression disease BEFREE However, the effect of GSK3β on HIF1α expression in osteosarcoma cells remains unknown. 24333432 2014
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE Knockdown of TRPM8 by siRNA in osteosarcoma cells leads to the impaired regulation of intracellular Ca(2+) concentration and then the Akt-GSK-3β pathway and the phosphorylation of p44/p42 and FAK are suppressed. 24391455 2013
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE The glycogen synthase kinase-3β/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells. 23164673 2013
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 Biomarker disease BEFREE Silencing or pharmacological inhibition of GSK-3β resulted in apoptosis of osteosarcoma cells. 22534782 2012
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.100 AlteredExpression disease BEFREE Celecoxib inhibited MG-63 cell viability, possibly by activating GSK-3β and inhibiting β-catenin-dependent gene transcription, suggesting a role for celecoxib in osteosarcoma treatment. 20926002 2010